摘要
结直肠癌(CRC)占所有癌症的10%,20%CRC患者初诊时为转移性结直肠癌(mCRC)。此外,高达50%的局限期患者最终会发生转移。通过探索mCRC的分子病理结构可为每个患者制定个性化的精准治疗方法。本文综述了在新兴的精准医疗时代下mCRC患者治疗方式的改进。事实上,分子分层虽然不能完全反映疾病的复杂性,但可为进一步精准个性化治疗提供依据。通过整合肿瘤基因改变、肿瘤微环境基因和蛋白质表达谱、宿主免疫能力以及将由此产生的动态变化应用到基于精准医学的连续过程中,期望能改善患者预后及预测治疗疗效,帮助临床医生在每个mCRC患者的疾病全流程中选择最合适的治疗方案。
Colorectal cancer(CRC)accounts for 10%of all cancers,and 20%of patients are metastatic CRC(mCRC)when is diagnosed.In addition,up to 50%of limited-stage patients will eventually develop metastases.By exploring the molecular pathological structure of mCRC,the personalized precision therapy is developed.This paper reviewed the improvement in the treatment of mCRC patients in the emerging era of precision medicine.In fact,molecular stratification does not fully reflect the complexity of the disease,but it provides the basis for further precise and personalized treatment.By integrating tumor gene changes,tumor microenvironment gene and protein expression profiles,host immunity,and applying the resulting dynamic changes to a continuous process based on precision medicine,it can improve patient prognosis and predict therapeutic efficacy,helping clinicians to select the most appropriate treatment for each mCRC patient throughout the disease process.
作者
宋嘉琪
汪妍
Naureen Starling
刘竹青
许青
Song Jiaqi;Wang Yan;Naureen Starling;Liu Zhuqing;Xu Qing(Department of Oncology,Shanghai Tenth People′s Hospital,Tongji University,Shanghai 200072,China;Shanghai circle harmony company,Shanghai 200025,China;Royal Marsden&Institute of Cancer Research,London KF12261,UK)
出处
《中华转移性肿瘤杂志》
2023年第2期175-177,共3页
Chinese Journal of Metastatic Cancer
基金
上海市科学技术委员会产学研医项目(18DZ1910102)
上海市申康医院发展集团医企融合创新协同专项(SHDC2022CRT009)
关键词
转移性结直肠癌
分子检测
精准治疗
Metastatic colorectal cancer
Molecular detection
Precision therapy
